Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CD34-positive cell intra-carotid injection for chronic ischemic stroke
jRCT2052200112Completed
- Sponsor
- Foundation for Biomedical Research and Innovation at Kobe
- Start
- Jun 2021
- Modality
- Stem Cell Therapies → Cell Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of autologous CD34-positive cells and granulocyte colony-stimulating factor in ischemic stroke (2 arms), sponsored by Foundation for Biomedical Research and Innovation at Kobe. Primary endpoint: Primary efficacy endpoint. Started Jun 2021; status: completed.
02
Drugs
autologous CD34-positive cellsgranulocyte colony-stimulating factor
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on jRCT2052200112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2052200112.